These findings justify further characterisation of the myeloid compartment of these tumours, as well as investigation of CDK12 alterations in forthcoming studies of ICB in PCa as a biomarker for stratification for single-agent ICB treatment. This evidence concerns the gene CDK12 and posterior cortical atrophy.